HCA Healthcare
HCA
439.17
+6.97
+1.61%
HCA Healthcare
US · HCA
#238 by market cap
Listed 1970
439.17
+6.97
+1.61%
Live - 5344 symbols - heartbeat 82s ago
· 2026-10-08 06:24
Pre-market
439.55
+0.09%
After-hours
439.22
+0.01%
Overnight
439.17
0.00%
- Market cap
- 95.08B
- P/E (TTM)i
- 14.73
- P/Bi
- -14.32
- EPSi
- 28.33
- Div yieldi
- 0.68%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on HCA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.65, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.08% YoY
Margins
- Gross margin
- 41.50%
- Operating margin
- 15.83%
- Net margin
- 8.97%
Key ratios & quality
- Enterprise valuei
- 140.88B
- PEG ratioi
- 2.33
- Altman Z-Scorei
- 2.65
PEG uses trailing P/E against the 3-year net income growth rate (6.33%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 46.68B | 51.34B | 51.53B | 58.75B | 60.23B | 64.97B | 70.60B | 75.60B |
| Gross profit | 17.53B | 19.30B | 19.29B | 22.49B | 23.18B | 25.58B | 28.68B | 31.37B |
| Selling & admin expenses | 21.43B | 23.56B | 23.87B | 26.78B | 27.69B | 29.49B | 31.17B | -- |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 6.64B | 7.22B | 7.26B | 9.68B | 9.05B | 9.63B | 10.55B | 11.97B |
| Pretax profit | 5.34B | 5.24B | 5.43B | 9.83B | 8.58B | 7.71B | 8.52B | 9.83B |
| Tax | 946.00M | 1.10B | 1.04B | 2.11B | 1.75B | 1.62B | 1.87B | 2.05B |
| Net profit | 4.39B | 4.15B | 4.39B | 7.72B | 6.83B | 6.09B | 6.66B | 7.78B |
| Basic EPS | 11 | 10 | 11 | 22 | 19 | 19 | 22 | 29 |
| Diluted EPS | 10.66 | 10.07 | 10.93 | 21.16 | 19.15 | 18.97 | 22.00 | 28.33 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 18.32B | 18.61B | 19.16B | 19.51B | 19.11B | 20.23B |
| Gross profit | 7.56B | 7.62B | 8.02B | 8.18B | 7.97B | 9.05B |
| Selling & admin expenses | 8.00B | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.86B | 2.97B | 2.97B | 3.18B | 2.86B | 3.07B |
| Pretax profit | 2.33B | 2.42B | 2.42B | 2.67B | 2.29B | 2.49B |
| Tax | 502.00M | 524.00M | 515.00M | 509.00M | 430.00M | 564.00M |
| Net profit | 1.83B | 1.89B | 1.90B | 2.16B | 1.86B | 1.93B |
| Basic EPS | 7 | 7 | 7 | 8 | 7 | 8 |
| Diluted EPS | 6.45 | 6.83 | 6.96 | 8.14 | 7.15 | 7.62 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 10.21B | 11.20B | 12.33B | 13.54B | 13.64B | 14.93B | 16.41B | 15.78B |
| Cash & ST investments | 502.00M | 621.00M | 1.79B | 1.45B | 908.00M | 935.00M | 1.93B | 1.04B |
| Inventory | 1.73B | 1.85B | 2.03B | 1.99B | 2.07B | 2.02B | 1.74B | 1.65B |
| Total assets | 39.21B | 45.06B | 47.49B | 50.74B | 52.44B | 56.21B | 59.51B | 60.72B |
| Total current liabilities | 7.57B | 7.76B | 8.70B | 9.58B | 9.90B | 12.66B | 15.18B | 16.35B |
| Short-term debt | 788.00M | 495.00M | 588.00M | 629.00M | 734.00M | 2.79B | 5.04B | 5.24B |
| Long-term debt | 32.03B | 33.58B | 30.80B | 34.34B | 37.71B | 37.17B | 38.33B | 41.60B |
| Total liabilities | 42,125,000,000.00 | 45,623,000,000.00 | 44,598,000,000.00 | 49,253,000,000.00 | 52,511,000,000.00 | 55,151,000,000.00 | 58,958,000,000.00 | 63,491,000,000.00 |
| Total equity | -2.92B | -565.00M | 2.89B | 1.49B | -73.00M | 1.06B | 555.00M | -2.77B |
| Retained earnings | -4.57B | -2.35B | 777.00M | -532.00M | -2.28B | -1.35B | -2.12B | -5.72B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 16.26B | 15.56B | 15.29B | 15.78B | 16.05B | 17.19B |
| Cash & ST investments | 1.06B | 939.00M | 997.00M | 1.04B | 940.00M | 1.01B |
| Inventory | 1.79B | 1.79B | 1.73B | 1.65B | 1.68B | 1.66B |
| Total assets | 59.80B | 59.54B | 59.75B | 60.72B | 61.45B | 63.25B |
| Total current liabilities | 13.63B | 15.94B | 17.90B | 16.35B | 19.26B | 17.31B |
| Short-term debt | 3.52B | 5.10B | 6.11B | 5.24B | 8.53B | 6.26B |
| Long-term debt | 41.06B | 39.38B | 38.40B | 41.60B | 39.49B | 43.45B |
| Total liabilities | 60,236,000,000.00 | 60,774,000,000.00 | 61,906,000,000.00 | 63,491,000,000.00 | 64,428,000,000.00 | 66,459,000,000.00 |
| Total equity | -438.00M | -1.24B | -2.16B | -2.77B | -2.98B | -3.21B |
| Retained earnings | -3.16B | -4.09B | -5.02B | -5.72B | -5.98B | -6.31B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 6.76B | 7.60B | 9.23B | 8.96B | 8.52B | 9.43B | 10.51B | 12.64B |
| Depreciation & amortization | 2.28B | 2.60B | 2.72B | 2.85B | 2.97B | 3.08B | 3.31B | 3.52B |
| Free cash flow | 3.19B | 3.44B | 6.40B | 5.38B | 4.13B | 4.69B | 5.64B | 7.69B |
| Dividends paid | -487.00M | -550.00M | -153.00M | -624.00M | -653.00M | -661.00M | -690.00M | -679.00M |
| Stock buybacks / issuance | -1.53B | -1.03B | -441.00M | -8.22B | -7.00B | -3.81B | -6.04B | -10.07B |
| Ending cash balance | 502.00M | 621.00M | 1.79B | 1.45B | 908.00M | 935.00M | 1.93B | 1.04B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.65B | 4.21B | 4.42B | 2.36B | 2.01B | 2.34B |
| Depreciation & amortization | 860.00M | 863.00M | 889.00M | 911.00M | 930.00M | 944.00M |
| Free cash flow | 660.00M | 3.03B | 3.13B | 870.00M | 895.00M | 1.10B |
| Dividends paid | -180.00M | -171.00M | -166.00M | -162.00M | -183.00M | -171.00M |
| Stock buybacks / issuance | -2.51B | -2.51B | -2.50B | -2.56B | -1.57B | -2.06B |
| Ending cash balance | 1.06B | 939.00M | 997.00M | 1.04B | 940.00M | 1.01B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| ROA %i | 9.99 | 8.32 | 8.11 | 14.16 | 10.94 | 9.65 | 9.95 | 11.28 |
| ROIC %i | -- | -- | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.19 | 13.77 | 13.61 | 19.40 | 17.14 | 14.84 | 14.99 | 15.98 |
| FCF / sales %i | 6.83 | 6.71 | 12.41 | 9.16 | 6.85 | 7.21 | 7.99 | 10.17 |
| Current ratioi | 1.35 | 1.44 | 1.42 | 1.41 | 1.38 | 1.18 | 1.08 | 0.97 |
| Quick ratioi | 0.96 | 1.03 | 1.02 | 1.00 | 0.99 | 0.86 | 0.84 | 0.73 |
| Debt / assetsi | 83.71 | 78.94 | 69.61 | 72.38 | 76.66 | 74.47 | 76.01 | 80.20 |
| LT debt / equityi | -- | -- | 5,676.22 | -- | -- | -- | -- | -- |
| Interest coveragei | 4.04 | 3.88 | 4.43 | 7.28 | 5.93 | 4.98 | 5.14 | 5.37 |
| Revenue CAGR (3Y) %i | 5.56 | 7.36 | 5.72 | 7.97 | 5.47 | 8.03 | 6.32 | 7.87 |
| Net income CAGR (3Y) %i | 21.16 | 6.64 | 19.21 | 22.47 | 17.20 | 11.77 | -6.10 | 6.33 |
| FCF CAGR (3Y) %i | 10.56 | 5.98 | 38.44 | 19.07 | 6.22 | -9.85 | 1.57 | 23.07 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 9.90 | 10.21 | 10.64 | 11.28 | 11.21 | 11.14 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.95 | 15.05 | 15.46 | 15.98 | 15.81 | 15.62 |
| FCF / sales %i | 6.91 | 10.03 | 10.89 | 10.17 | 10.38 | 7.69 |
| Current ratioi | 1.19 | 0.98 | 0.85 | 0.97 | 0.83 | 0.99 |
| Quick ratioi | 0.89 | 0.72 | 0.64 | 0.73 | 0.64 | 0.77 |
| Debt / assetsi | 77.65 | 77.88 | 77.58 | 80.20 | 81.11 | 81.51 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 5.10 | 5.07 | 5.22 | 5.37 | 5.29 | 5.26 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Operating hospitals and related health care entities100.00%
Quote time 2026-10-08 06:24:33 · For reference only, not investment advice and not tailored to your situation.